For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...

Regeneron and Sanofi’s Dupixent trial shows major improvement in allergic fungal rhinosinusitis symptoms in patients 6+. Read ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and ...

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

A study has found that people with eczema are able to bathe either daily or weekly, without any impact on their symptoms.

A systematic review reports that monoclonal antibodies and JAK inhibitors can be effective in the treatment and clearance of ...

May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following the ...

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

We’ve talked about glycerin and how it’s hyaluronic acid’s inexpensive alternative, but Sass doesn’t recommend buying pure ...